Not all severe asthma patients are getting the specialist care they need.

11 __________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Living in Limbo: Asthma UK report1


Graphic summarising data from the from the Asthma UK: Living in Limbo 2019 report demonstrating the limited access for severe asthma patients to biologic treatment and specialist care and the consequences of this unmet need.

Patients should be under specialist asthma care if they have2,3:

  • Required high-dose therapies to control symptoms*
  • Been prescribed daily OCS* or two or more courses of oral or injected corticosteroids in the previous 12 months to control symptoms
  • Been admitted to hospital in the previous 12 months
  • Had two or more visits to the emergency department with an asthma attack in the previous 12 months

*BTS/SIGN guidance.


Accelerated Access Collaborative (AAC):


Graphic summarising findings from a review of the patient journey to a biologic in UK severe asthma centres comparing recognised patient needs versus current reality.

A&E, accident and emergency; BTS, British Thoracic Society; NRAD, National Review of Asthma Deaths; OCS, oral corticosteroids; SAA, severe allergic asthma; SIGN, Scottish Intercollegiate Guidelines Network.


  1. Asthma UK. Living in Limbo: the scale of unmet need in difficult and severe asthma. 2019. Available at: [Accessed April 2020].
  2. Royal College of Physicians. National Review of Asthma Deaths: why asthma still kills. 2015. Available at: [Accessed April 2020].
  3. British Thoracic Society. BTS/SIGN British Guideline on the Management of Asthma. 2019. Available at: [Accessed April 2020].
  4. NICE. Asthma Biologics - Adoption Barriers and Suggested Solutions. Available at: [Accessed May 2022].
  5. APPG. Improving Asthma Outcomes In The UK – ONE YEAR ON. Available at: [Accessed May 2022].
  6. Accelerated Access Collaborative. A review of the patient journey to a biologic in UK severe asthma centres.
  7. NHS Digital. Innovation Scorecard. Available at: .
Rate this content: 
No votes yet
UK | September 2022 | 225865

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]